ADC / breast oncology

Antibody-drug conjugates competing across HER2-low, HER2+, and TROP2 breast segments.

LensesCash lens — fade names that may not fund to the gateEvidence lens — thicker = stronger published data

EarlierApproval →

Enhertu HER2 ADC (partnered) · NCT03734029 · Breast ADC label / earlier-line update

Patritumab deruxtecan class · NCT05338970 · ADC Phase 3 update

TROP2 / precision oncology ADC path · NCT05415709 · Breast / solid tumor ADC update

Next-gen ADC · NCT06105671 · ADC early data

Bispecific IO oncology · NCT04900818 · Dose escalation